EBG MEDAUSTRON GMBH

Their core work

MedAustron is one of Europe's few ion beam therapy centres, located in Wiener Neustadt, Austria, providing advanced cancer treatment using proton and heavy ion beams. Beyond clinical operations, the facility contributes to accelerator physics research, radiobiology, and medical isotope science through participation in EU research infrastructures. Their work spans treatment planning optimization, beam diagnostics, Monte Carlo simulations for dose calculation, and the development of next-generation accelerator technologies including superconducting components.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2020), MedAustron focused on optimizing the core physics of particle therapy — beam diagnostics, Bragg peak characterization, Monte Carlo dose simulations, and treatment planning for ion beams. From 2021 onward, their work expanded in two directions: scaling up heavy ion therapy infrastructure (superconducting gantries, advanced beam delivery) and moving into medical isotope production and radiopharmaceuticals for precision cancer treatment. This shift signals a move from being purely a therapy facility toward becoming a multi-purpose medical physics research infrastructure.

MedAustron is broadening from treatment delivery into upstream research — isotope production, superconducting accelerator components, and theranostics — positioning itself as a comprehensive medical physics research hub.

How they like to work

MedAustron operates exclusively as a participant or third party, never coordinating projects, which is typical for a specialized clinical-research facility contributing domain expertise to larger consortia. With 76 unique partners across 21 countries, they work in broad European networks rather than small focused teams. This pattern suggests they are a sought-after infrastructure partner — groups come to them for access to their ion beam facility and clinical expertise.

MedAustron has collaborated with 76 distinct partners across 21 countries, giving them a wide European network concentrated in the medical physics and nuclear research communities. Their reach spans the major accelerator and therapy centres across Europe.

What sets them apart

MedAustron is one of only a handful of dual-use ion therapy centres in Europe that combine active patient treatment with research infrastructure open to international collaborators. As an SME rather than a university hospital, they bring operational agility and a practical focus on technology transfer. For consortium builders in medical physics or oncology, they offer both clinical validation capability and access to a working heavy ion beam facility — a rare combination.

Highlights from their portfolio

• HITRIplus
  Their largest funded project (EUR 375,807), focused on next-generation heavy ion therapy including superconducting gantry development — a major engineering challenge in the field.
• OMA
  A comprehensive MSCA training network (EUR 255,934) covering the full chain from accelerator physics to clinical oncology, where MedAustron contributed across multiple work packages.
• PRISMAP
  Represents MedAustron's expansion into medical isotope production and targeted radiotherapy — a new direction connecting accelerator physics with nuclear medicine.